Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the Treatment of Pericarditis

 Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the Treatment of Pericarditis

Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the Treatment of Pericarditis

Shots:

  • The approval is based on the P-III RHAPSODY trial involves assessing Arcalyst (SC, qw, 300mg followed by 160mg) vs PBO in adults and children aged ≥12yrs. in a ratio (1:1) with recurrent pericarditis
  • The result showed a 96% reduction in the risk, with pain- free or minimal pain days (92% vs 40%), sustained reductions in both reported pain and inflammation as early as the first dose & improvement in clinical outcomes
  • Arcalys (rilonacept) is a recombinant dimeric fusion protein that blocks IL-1α and IL-1β signaling and is expected to be available in Apr’21. Additionally, the company launches the One Connect patient support program to assess patients on their treatment journey

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Kiniksa

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post